Pink Sheet
>>US FDA Performance Tracker

One Prediction For US FDA Under Biden: More Advisory Committees

29 Jan 2021

• By Michael McCaughan

The US FDA was extraordinarily selective in its use of advisory committees for new drug applications in 2020. It is safe to bet that trend will change under President Elect Biden’s team.

Rostrum with microphone and computer in conference hall — Could the US FDA return to in-person advisory committees this year?

The start of the New Year is a good time for making predictions, so here is one: look for the US Food & Drug Administration to start convening advisory committees more frequently once the new team takes over under President-Elect Joe Biden.

FDA held just 18 reviews of pending new drug applications in 2020, the fewest since 2007. (Arguably it was even...